NEW YORK (GenomeWeb News) – Anticipating the expected launch of the Life Technologies' Ion Proton benchtop sequencer, Oppenheimer analyst David Ferreiro today estimated 140 placements of the system in 2012 translating to $35.3 million in revenues.

He added that he estimates 200 placements of Ion Proton in 2013 and 300 placements in 2014, which would result in revenues of $75 million and $150.7 million, respectively.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.